Roche and
Under the partnership,
Zilebesiran is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT). The treatment inhibits the synthesis of AGT in the liver. This potentially leads to durable reductions in AGT protein and ultimately, in the vasoconstrictor angiotensin (Ang) II. It could therefore help treat hypertension patients who have a high cardiovascular risk.
"We are excited to work together with Alnylam… to further develop and provide this promising therapy with best-in-disease potential to patients," stated
"With this collaboration, we now can develop zilebesiran in a more robust way, allowing us to have cardiovascular outcomes data in hand at launch," commented
Under the agreement, Roche and
How effective is zilebesiran in lowering blood pressure?
Based on positive Phase 1 data, compared to placebo, zilebesiran was associated with dose-dependent reductions in serum angiotensinogen (AGT).
Results revealed tonic blood pressure control with consistent and durable blood pressure reduction throughout a 24-hour period, sustained up to six months after single doses of ≥200mg. Due to its potential to be administered through a biannual subcutaneous dosing regime, zilebesiran could improve patient adherence and compliance.
In addition, zilebesiran could provide patient benefit in additional cardiovascular indications with high unmet medical need.
Zilebesiran is currently in a Phase II trial as a treatment for hypertension. In the Phase II clinical programme, is being evaluated as either as a monotherapy (KARDIA-1) or in combination with one of three standard-of-care antihypertensive medications (KARDIA-2).
Adding to its therapeutic portfolio, earlier this month, Roche agreed to obtain a global license for KSQ Therapeutics' small molecule USP1 inhibitor as a treatment for solid tumours.
The post Roche to co-develop hypertension RNAi therapeutic appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2023. All Rights Reserved., source